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Abstract
Mitoxantrone is one of the few drugs approved for the treatment of progressive multiple sclerosis (MS). However, the
prolonged use of this potent immunosuppressive agent is limited by the appearance of severe side effects. Apart from its
general cytotoxic effect, the mode of action of mitoxantrone on the immune system is poorly understood. Thus, to develop
safe therapeutic approaches for patients with progressive MS, it is essential to elucidate how mitoxantrone exerts it benefits.
Accordingly, we initiated a prospective single-arm open-label study with 19 secondary progressive MS patients. We
investigated long-term effects of mitoxantrone on patient peripheral immune subsets using flow cytometry. While we
corroborate that mitoxantrone persistently suppresses B cells in vivo, we show for the first time that treatment led to an
enrichment of neutrophils and immunomodulatory CD8
low T cells. Moreover, sustained mitoxantrone applications
promoted not only persistent NK cell enrichment but also NK cell maturation. Importantly, this mitoxantrone-induced NK
cell maturation was seen only in patients that showed a clinical response to treatment. Our data emphasize the complex
immunomodulatory role of mitoxantrone, which may account for its benefit in MS. In particular, these results highlight the
contribution of NK cells to mitoxantrone efficacy in progressive MS.
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Introduction
Multiple sclerosis (MS) is the most common autoimmune
disease of the central nervous system (CNS) leading to severe
disability in young adults. It is considered to be initiated by
autoreactive T cells that recognize CNS antigens, and in concert
with numerous immune cells orchestrate an inflammatory reaction
which eventually results in demyelination and neuroaxonal
damage [1]. The most typical disease course is relapsing-remitting
MS (RRMS) characterized by total or partial recovery after
attacks. Most patients initially displaying a relapsing-remitting
course eventually convert to a secondary progressive disease
course (SPMS) after 10–25 years of disease [2].
Current therapies for MS focus mainly on immune aspects of
the disease and benefit principally patients with RRMS, while
their efficacy is minimal or even lacking in patients with primary
progressive disease. Mitoxantrone (MX) is one of the few
treatments licensed for use in SPMS [3]. MX is an anti-neoplastic
anthracenedione derivative that inhibits DNA replication and
induces single and double strand breaks by intercalating in DNA
through hydrogen bonding [4]. The mechanisms of action of MX
are still not fully understood, and clear data on its effects on the
immune system are limited [5]. Although MX has shown
effectiveness in SPMS [6], a substantial proportion of patients fail
to respond to treatment, and thus there is an urgent need to
identify markers that allow the prediction of individual treatment
responses. Moreover, the administration of MX is limited to a
treatment-period of 2–3 years by the cumulative dose-dependent
risk of severe adverse effects, such as cardiotoxicity [7–11] and
potential leukemia development [12]. Nevertheless, understanding
how MX benefits SPMS patients is essential for establishing safer
and more effective treatments for this group of patients. Therefore,
we conducted a longitudinal study on an SPMS cohort, analyzing
intra-individual comparisons (baseline versus treatment) of major
populations of peripheral blood lymphocytes using flow cytometry.
Methods
Study Design and Participants
A prospective monocentric single-arm open-label study design
was used to evaluate the effects of MX treatment on immunolog-
ical parameters in MS patients. The study was approved by the
ethics committee of the Charite ´ – University Medicine Berlin and
was conducted in accordance with the Declaration of Helsinki, the
guidelines of the International Conference on Harmonization of
Good Clinical Practice, and the applicable German laws. All
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and enrolled at the neuroimmunology outpatient clinic of the
Charite ´ – Universitaetsmedizin Berlin in Germany. Inclusion and
exclusion criteria are summarized in Table 1. Patients received
MX according to the standard protocol [6], meaning that unless
dose reduction was required owing to side effects such as
hematological abnormalities, an MX dose of 12 mg/m
2 body
surface area (BSA) was applied intravenously every three months
up to a cumulative dose of 140 mg/m
2 BSA. Treatment with
other cytotoxic or immunomodulatory drugs was prohibited
during the study.
In this study, we aimed to determine the persistent effects of
MX that may account for its long-term benefit in SPMS.
Therefore, study-related clinical assessment and blood sampling
for evaluation of immunological parameters was done immediately
before the next subsequent MX administration, i.e. three months
after the previous MX-infusion. Clinical examination and
venipunction occurred at baseline, after six months (directly prior
to the third MX cycle) and after twelve months (directly prior to
the 5th MX cycle). As controls, we included 10 RRMS patients
with no sign of disease activity (mean EDSS of 2), as well as 8
healthy controls. Both groups were gender and age matched.
Reagents
Human Fc fragment was purchased from Calbiochem (Merck
Chemicals Ltd., Darmstadt, Germany). The following antibodies
were used: against CD3 (AlexaFluor700), CD16 (Pacific Blue),
CD62L (APC), CD4 (PerCP), CD8 (FITC), CD14 (FITC), CD19
(PE) from Becton-Dickinson (Heidelberg, Germany); CD56
(FITC), CX3CR1 (PE) from MBL (Nagoya, Japan); CD27 (PE-
Cy7) from eBioscience (San Diego, CA); CD57 (APC), NKp30
(APC), NKp46 (APC), KIR2DL1/2DS1, KIR3DL1/3DL2 (APC)
from Miltenyi Biotech (Bergisch-Gladbach, Germany); CD94/
NKG2A (PerCP) and KIRDL2/2DS2/2DL3 (APC) from R&D
KIR3DL1/3DS1 (APC) from Beckman Coulter (Krefeld, Ger-
many).
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were obtained
from heparinized peripheral blood from the patients and isolated
by density gradient centrifugation (Percoll, Nycomed Pharma,
Roskilde, Denmark) according to the manufacturer’s instructions.
PBMC were then cryopreserved in liquid nitrogen for later
analysis.
Flow Cytometry Analysis
For ex vivo investigation, whole blood was lysed, washed, and
stained with antibodies against CD14, CD19 or CD3/CD4/CD8
to identify monocytes, B cells or T cells, respectively. Neutrophils
were identified based on gating on the granulocyte population in
the forward and sideward scatter profile, and CD16 positivity.
For the phenotype characterization of natural killer (NK) cell
subpopulations, thawed PBMCs were washed and incubated with
antibodies against CD3, CD56, CD16, CX3CR1, CD62L, CD57,
CD27, CD94/NKG2A, NKp30, NKp46, and panKIR
(KIR2DL1/2DS1/2DL2/2DS2/2DL3/3DL1/3DL2/3DS1) as
described previously [13]. Absolute cell numbers were determined
with the use of TrueCount beads (BD). Data were analyzed using
the FACS DIVA software.
Statistical Analysis
The paired t-test was used to calculate p-values for comparisons
between two groups (i.e. baseline versus six months and baseline
versus 12 months). Repeated measures ANOVA was used for
comparisons between three groups (i.e. baseline versus six and 12
months), with the Tukey post-hoc test. Statistical significance was
defined as p,0.05, and depicted as *p,0.05; **p,0.01;
***p,0.001. One-way ANOVA with the Bonferroni post-hoc test
was used to compare baseline and 12 months of treatment with
healthy controls and with RRMS patients. We verified that the
data conformed to a Gaussian distribution. Statistical significance
was depicted as # p,0.05; ### p,0.001.
Results
Cohort Description
Of the 19 SPMS patients screened, 15 patients were included
in this study because four patients did not conform to the
eligibility criteria. From the 15 patients enrolled, two patients
dropped out before receiving the third MX dose because of
intolerability, and one patient terminated MX treatment before
receiving the 5
th dose because of severe disease progression. The
remaining twelve patients completed the study period of twelve
months.
In accordance with the pivotal MX trial in MS [6], clinical
assessment of therapy response was based primarily on the EDSS
and secondarily on the occurrence of relapses. Those patients who
improved or remained stable on the EDSS throughout the study
period and who did not experience any relapses were considered
Table 1. Inclusion and exclusion criteria of the study.
Inclusion criteria N definite diagnosis of MS according to the 2001 McDonald criteria
N active disease defined by at least two relapses and/or progression by at least one point on the expanded
disability status scale (EDSS) in the preceding 18 months which was not sufficiently controlled by interferon beta
or glatiramer acetate
N EDSS score of 3–6.5
N at least two months free of treatment with interferon-beta or glatiramer acetate
N no relapse or steroid treatment four weeks prior to enrolment
N no prior treatment with immunosuppressants
Exclusion criteria N pregnancy or breast feeding
N cardiac disease
N severe leucopenia
N inability to provide informed consent
doi:10.1371/journal.pone.0039625.t001
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experienced a new relapse or both where classified as non-
responders. Altogether, five patients were classified as treatment
responders and eight patients as non-responders to MX treatment.
The demographic and clinical features of these patients are
summarized in table 2.
Effects on MX Treatment on the Frequency of Peripheral
Immune Cell Populations
In order to apprehend the persistent effects of MX on the
immune system in SPMS patients, we first determined the effect of
the treatment on neutrophils, monocytes and T and B lympho-
cytes in whole blood, directly after venipunction at baseline and
three months after six months and 12 months of treatment
(Figure 1).
MX treatment did not affect the populations of CD14
+
monocytes, CD4
+ Th or conventional CD8
high T cells at these
time points (Figure 1B). In contrast, we observed a significant
increase of a subset of immunomodulatory CD8
low T cells at six
and 12 months (repeated measures ANOVA, p =0.0002) as
well as an increase in the frequency of neutrophils at month 12
(repeated measures ANOVA, p =0.044, Figure 1C). Moreover,
confirming previously reported data, the B cell population was
persistently reduced during the entire observation period
(repeated measures ANOVA, p,0.0001, Figure 1C). Further-
more, in order to elucidate if MX-induced alteration of the
proportion of B cells, CD8
low T cells and neutrophils reflected a
restoration toward normal cell levels observed in healthy
individuals or to levels observed in stable patients, we assessed
the percentages of these three immune cell populations in a
gender and age-matched cohort of RRMS patients with mild
and stable disease, and in a matched group of healthy controls.
Figure 1D shows that only in the case of the immunomodu-
latory CD8
low T cell population, MX treatment seems to restore
the proportion of these cells to levels observed in healthy
controls (one-way ANOVA p =0.015). No significant difference
was observed between frequencies of CD8
low T cells before or
after MX application and the levels observed in stable MS
patients. In contrast, the MX-induced neutrophil enrichment
does not seem to reflect any trend towards normalization since
the proportion of neutrophils at 12 months was also significantly
elevated, compared to both healthy controls and stable MS
patients (one-way ANOVA p =0.001). Likewise, the selective
depletion of B cells during MX treatment cannot be considered
as a normalization of immune cell proportion, at least in terms
of absolute numbers.
We also examined the effects of MX on NK cells in fresh blood
and observed an increased frequency of NK cells at six months. In
light of this observation, we conducted a more detailed analysis of
these cells in subsequent investigations using frozen material, in an
attempt to clarify specifically how the NK cell compartment is
modulated during MX treatment.
Effects of MX Treatment on Frequency and Absolute
Numbers of Circulating NK Cells
We then analyzed NK cells at the different time points using
thawed PBMCs. NK cells were first categorized according to their
expression of CD56 and CD16 in the well defined subsets of
CD56
dim and CD56
bright NK cells (Figure 2A). Using a more
comprehensive set of markers, we could confirm a significant
increase of the total NK cell frequency during the first part of the
study, i.e. after six months of treatment (Figure 2B). This initial
increase receded in the latter stages after 12 months of treatment
(repeated measures ANOVA, p =0.001). Also here, we examined
whether MX effects on NK cells reflected a restoration toward NK
cell frequencies observed in healthy individuals. As shown for B
cells and neutrophils, MX treatment seems not to restore the
proportion of NK cells or their subsets to levels observed in healthy
controls (Figure 2C). Interestingly, we did not observe any increase
of the absolute NK cell numbers during treatment, indicating that
Table 2. Clinical data of the 15 SPMS patients included in the study.
Patients Sex Age (years)
Disease
duration
(months) EDSS Relapses Response
Start MX Disease onset Base line Month 6 Month 12 Month 18
1 m 42 36 69 4.0 4.0 4.0 4.0 no R
2 m 44 39 57 3.5 3.0 3.0 3.0 no R
3 m 34 31 36 5.5 6.0 6.5 6.5 yes (2x) NR
4 f 55 36 225 6.5 6.5 nd nd no na
5 m 41 37 46 5.5 6.0 6.0 6.5 no NR
6 m 49 32 207 5.5 5.5 5.5 nd yes NR
7 m 30 18 144 5.5 5.5 5.5 5.5 no R
8 f 35 30 65 3.5 3.5 4.0 4.0 no NR
9 m 40 23 204 5.5 6.0 6.0 nd no NR
10 f 51 46 55 4.0 4.0 4.5 4.5 no NR
11 m 53 43 120 4.0 5.5 nd nd no NR
12 m 66 46 246 6.5 7.0 7.0 nd no NR
13 m 37 26 133 6.5 6.5 7.0 6.5 no R
14 f 57 35 263 5.0 5.0 4.0 4.0 no R
15 m 52 32 240 6.0 6.0 nd nd no na
nd, not determined; R, responder; NR, non-responder; na, not available.
doi:10.1371/journal.pone.0039625.t002
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to the depletion of other major immune cell populations
(Figure 2D).
Effects of MX Treatment on Maturation and
Differentiation of Circulating NK Cells
Next, we focused on the effects of MX on the distinct NK cell
subsets, the cytotoxic CD56
dim and immunomodulatory
CD56
bright NK cells. The frequency of both CD56
dim and
CD56
bright NK cells increased concomitantly after six months of
treatment (Figure 2B) (repeated measures ANOVA, p=0.004 and
0.029, respectively). Again the analysis of absolute cell numbers
did not show any statistically significant differences in these
populations (Figure 2C) confirming the interpretation of a general
and non-specific enrichment of all NK cells at six months.
Moreover, neither total NK cells nor CD56
dim and CD56
bright NK
cell evolution after treatment presented normalization to the
healthy control levels (Figure 2C). We and others have recently
reported on different stages of NK cell subsets, cell maturation
with distinct functional properties that can be characterized by the
expression of specific markers including CD27 [14], CD57 [15],
CD62L [16], or CX3CR1 [13].
To determine the effects of MX on the NK cell maturation and
activation phenotype, we analyzed an array of NK cell markers at
months six and 12 of treatment. Although at month six the NK
cell phenotype appeared not to be affected, we did observe a long-
term MX-associated reduction of CD62L expression (p =0.025),
which is indicative of a process of maturation [16]. The expression
of CD27 and CD57 remained unaltered (Figure 3A).
Moreover, to prove that this maturation process is coupled to
the regulation of NK cell receptors, we examined the expression of
the activatory receptors NKp30 and NKp46, and the inhibitory
receptors CD94/NKG2A and panKIR, which are known to be
regulated during NK cell maturation [13]. Our data show that,
coinciding with maturation, both NKp46 (p=0.041) and NKp30
(p=0.004) were decreased after treatment (Figure 3B). No changes
were detected in the inhibitory receptors CD94/NKG2A and
killer cell immunoglobulin-like receptors (panKIR) (data not
shown). Thus, altogether these results indicate that MX promoted
a shift towards a more mature NK cell phenotype, as reflected by
the downregulation of CD62L as well as NKp46 and NKp30.
However, these changes in NKp30, NKp46 and CD62L
expression did not reflect any trend toward a restoration to
healthy control levels (data not shown).
Association of the Clinical Response to MX and the
Modulation of NK Cells
In Figure 3, we show a heterogeneous picture on NK cell
modulation by MX. Since regulation of NK cells has been
associated with response to diverse MS therapies such as
daclizumab or interferon beta therapy [17,18], we asked whether
changes in NK cell status may correlate with the treatment
response. The cohort of patients was stratified into responders and
non-responders to treatment, according to the response criteria
described above. Even despite the limited sample size, we
demonstrate that maturation, reflected by the downregulation of
CD62L (p=0.029), NKp46 (p=0.032) and NKp30 (p=0.020),
occurred exclusively in the cohort of responders (Figure 4A). In
contrast, patients that did not benefit clinically from MX
treatment showed no significant alterations of the various NK
cell markers examined here (Figure 4B).
Discussion
To address the specific and persistent effects of MX treatment
on different immune cell subpopulations in SPMS patients, we
conducted a longitudinal study on a cohort of 15 SPMS patients.
Using flow cytometry, we compared intra-individually (baseline
versus treatment) major populations of peripheral blood lympho-
cytes including NK cells. We demonstrated that, apart from being
cytotoxic for B lymphocytes, MX promoted the enrichment of
peripheral neutrophils as well as of subsets of CD8
low T
lymphocytes and of NK cells. In addition, we observed that
sustained MX treatment induced a shift in the maturation of
circulating NK cells which was associated with clinical response to
MX treatment.
Our initial results addressed the effects of MX treatment on
major blood cell populations (Figure 1). We showed a dramatic
depletion of B cells following MX treatment. The baseline B cell
levels in these patients were comparable to levels seen in stable MS
patients and healthy controls (Figure 1D), therefore the MX-
induced depletion cannot be considered as a normalization of an
atypical elevated proportion of B cells, at least in term of quantity.
B cell depletion by MX was previously reported by other groups
both as an immediate and a persistent consequence of the MX
therapy in vivo [19]. Moreover, Chan et al. demonstrated that
already 1 h after MX infusion not only B cells but also CD8
+
T cells underwent apoptosis [20]. We did not observe any effects
of MX on T cells, which is consistent with the results reported by
Gbadamosi et al. [19]. Thus, the immediate MX-induced
apoptosis of CD8
+ T cells is probably a transient phenomenon.
However, we observed a strong and consistent increase in the
frequency of a subset of CD8 T cells characterized by a lower
expression of the CD8 co-receptor.
CD8
low T cells are less cytotoxic than CD8
high T cells, and they
express IL-4, IL-10, and interferon-gamma [21]. CD8
low lympho-
cytes, and in particular CD8
low NK cells have been shown to be
reduced in untreated patients with clinically isolated syndrome and
MS [22]. Interestingly, MX appears to restore the frequency of
CD8
low T cells to the levels observed in healthy individuals
(Fig. 1D), suggesting that this regulation may contribute to the
efficacy of the treatment in MS. In any case, it is evident that
investigations on the role of CD8
low T lymphocytes in MS and
Figure 1. MX treatment leads to a persistent reduction of B cells and enrichment of neutrophils and CD8
low T cells. Peripheral blood
samples from SPMS patients were surface stained for CD16, CD19, CD14, CD3, CD4, and CD8. (A) A representative flow cytometry dot plot shows the
gating strategy for leucocytic populations: R1, comprising all cells without the debris and R2, representing the lymphocytes. Representative flow
cytometry plots showing MX-induced changes over time in neutrophils, B cells and CD8
low T cells. (B) The T helper cell (CD4+), the cytotoxic T cell
(CD8
high), and the monocyte (CD14+) populations did not change over time. (C) The B cell (CD19+) population decreased significantly after six
months and 12 months of treatment. The cytotoxic T cell (CD8
low) population increased significantly after six months and 12 months of treatment,
and the neutrophil (CD16+) population was enriched after 12 months of treatment. (D) Comparison of frequencies of B cells, CD8
low cells and
neutrophils before and after treatment and in patients with stable MS and healthy individuals. B cell levels presented no difference. CD8
low T cell
levels after 12 months of treatment were normalized to healthy controls levels. Neutrophil levels after 12 months of treatment were increased
compared to the controls. Repeated-measures ANOVA *p,0.05; **p,0.01; ***p,0.001; One-way ANOVA #p,0.05; ###p,0.001. FSC, forward
scatter; SSC, side scatter; mth, months.
doi:10.1371/journal.pone.0039625.g001
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treatment are worthwhile topics for future investigations.
We also observed an increased frequency of peripheral
neutrophils in MX-treated patients, the proportion of which is
elevated even when compared to control stable patients or to
healthy individuals (Fig. 1D). This was an unexpected result, as
MX was reported to normalize IL-6 production [23], a cytokine
that together with G-CSF is known to induce neutrophil
production [24]. Neutrophil infiltration into the CNS has been
associated with the acute EAE phase [25] and with early axonal
pathology in EAE [26]. A recent report indicates that neutrophils
may also contribute to MS pathogenesis, as patients display
elevated numbers of pre-activated or primed neutrophils in
peripheral blood [27]. It is not clear whether neutrophil activity
or phenotype are altered by MX treatment. Since an elevated
frequency of neutrophils was observed in both responders and
non-responders (data not shown), one may speculate that the
observed effect was not related to the efficacy of MX treatment.
Similarly, the elevated frequency of CD8
low T cells did not appear
to be associated with clinical response to MX.
In our study, MX induced an enrichment of the NK cell
population after six months of treatment, which subsequently
stabilized by month 12 (Figure 2). This was an unexpected finding
in view of the potent immunosuppressive function of MX on other
lymphocyte populations [28–30].
To better understand how MX treatment influences NK cell
phenotype, we investigated the treatment effects on NK phenotype
and activity. We showed that at six months of treatment, both the
cytotoxic CD56
dim and the immunomodulatory CD56
bright
subpopulations were enriched, without any shift to a particular
phenotype. Moreover, MX seems not to restore the frequency of
NK cells and their subsets to healthy control levels as shown in
Figure 2C. Elevated frequencies of total NK cells or of the
CD56
dim and CD56
bright subsets were not accompanied by an
elevation of absolute NK cell numbers. Thus, NK cell enrichment
seemed to be the indirect consequence of the dramatic suppression
of other immune populations, primarily B cells (Figure 1).
Interestingly, prolonged MX treatment did not further affect
immune cell frequencies, but appeared to modulate immune cells
in a more specific way. In particular, we observed a significant
reduction in the frequency of circulating immature NK cells after
Figure 2. MX treatment promotes NK cell enrichment. Thawed PBMCs from SPMS patients were stained for NK cells and major subsets using
CD56 and CD16. (A) Representative flow cytometry plots show the NK cell gating strategy and MX-induced changes over time in NK cells. (B) Shows
the population percentages. After six months of treatment, the NK cell population was significantly enriched and then decreased from six to 12
months of treatment. The CD56
dim and CD56
bright NK cells subsets were significantly increased after six months of treatment, but no difference was
detected from six to 12 months. (C) Frequencies of NK cells and NK cell subsets in SPMS patients before and after MX treatment compared to the
frequency observed in matched healthy individuals. (D) Shows absolute counts of NK cells and CD56 subsets: NK cells, CD56
dim and CD56
bright NK cell
subsets remained unchanged over time. *p,0.05; **p,0.01; FSC, forward scatter; SSC, side scatter; mth, months; ns. non significant.
doi:10.1371/journal.pone.0039625.g002
Figure 3. MX treatment induces NK cell maturation. Thawed PBMCs from MX-treated SPMS patients were stained for expression of CD62L,
CD27, CD57, NKp30, and NKp46 on NK cells. (A) Following 12 months of treatment, the population of cells expressing the maturation marker CD62L
decreased, but no change was detected for CD27 and CD57 expressing NK cells. (B) The population of cells expressing the activatory receptors NKp46
and NKp30 showed a significant decrease after 12 months of treatment. *p,0.05; **p,0.01; mth, months.
doi:10.1371/journal.pone.0039625.g003
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ulate the expression of CD27, CD57 and CD62L [16] as well as
the expression NKp30 and NKp46 activatory receptors and the
inhibitory CD94/NKG2A receptor complex. Here, we showed
that at 12 months of treatment, the maturation marker CD62L
and the activatory receptors NKp46 and NKp30 were significantly
downregulated, suggesting a late and persistent effect of MX on
the maturation of circulating NK cells. This could be in part the
consequence of the expected elevated susceptibility of immature
proliferating NK cells to MX-induced cytotoxicity. Indeed, we
previously demonstrated that immature NK cells proliferate much
better than mature NK cells in response to IL-2. [13]. However,
that cytotoxicity alone may not entirely explain this rather late
effect of the treatment, which manifested only after repeated
applications of MX, at 12 months. It was previously reported that
MX treatment enhances the expression of Th2-related cytokines
[31]. IL-4 is known to induce NK cell maturation [32]. Therefore,
we speculate that MX promoted enhancement of IL-4 production
may also contribute to NK cell maturation in treated patients.
Similarly, in agreement with the report of Kienzle et al. on the
generation of CD8
low T cells in the presence of IL-4 [33], the
strong IL-4 production induced by MX may contribute to the
expansion of CD8
low T cells observed in our study.
In MS, deficient NK cell activity has been extensively reported
by several groups during the last 40 years [34–37]. Thus, the
observed increased frequency of mature and active NK cells may
contribute to the benefit of MX in patients with MS, although we
could verify that MX treatment did not restore NK cells to a
maturation or activation status observed in healthy donors.
Treatment-related enrichment of particular NK cell subsets, or
induction of NK cell activation has been associated with the
therapeutic success of numerous MS drugs including interferon-
beta, glatiramer acetate, and daclizumab [17,18,38–40]. Stratify-
ing our data according to MX response revealed that the elevated
frequency of mature NK cells was observed exclusively in patients
that responded to the therapy (Figure 4). This result is especially
promising, considering the robust significance seen in this
relatively limited data set. Moreover, of all the effects of MX we
observed here, only the NK cell effects were related to the clinical
response to MX. It remains elusive why NK cell maturation
occurred primarily in patients that responded to the treatment.
The fact that both responder and non-responder patients showed
the same ratio of immature/mature peripheral NK cells at
baseline suggests that baseline differences between the two patient
groups likely did not account for this effect. Thus far, we have not
explored additional factors, such as selective production of Th2-
cytokines [31] or selective alteration of the functionality of antigen-
presenting cells [41], which may contribute directly or indirectly to
NK cell maturation, and which may also differ in responders and
non-responders.
Thus, while alteration of immune cell frequencies in the
peripheral blood was an early and sustained effect of MX in MS
patients, the alteration of NK cell phenotype appears to be a later
mechanism of action (observed only after 12 months of treatment),
related to the clinical benefits of the treatment.
In conclusion, we have shown for the first time that the NK cell
population is promoted by MX treatment in vivo, accompanied by
a shift towards a mature NK cell phenotype associated with the
response to the therapy. The contribution of NK cells to beneficial
Figure 4. MX-induced NK cell maturation is associated with the clinical response. Thawed PBMCs from SPMS patients stratified into
responders and non-responders to MX, were stained for expression of CD62L, CD27, CD57, NKp30, and NKp46 on NK cells. (A) Following 12 months of
treatment the responder cohort showed decreased CD62L, NKp46 and NKp30 expression on NK cells. (B) The non-responder cohort did not show any
difference in CD62L, NKp46 and NKp30 expression. *p,0.05; mth, months.
doi:10.1371/journal.pone.0039625.g004
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and safe treatments for progressive MS.
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